No direct trial exists, but cross-trial comparison of SURMOUNT-1 and the retatrutide Phase 2 places mean weight loss ~2× higher for retatrutide at matched timepoints.
Read the piece →Eli Lilly's Phase 2 obesity trial for retatrutide reported up to 24.2% mean weight reduction at 48 weeks. Here's the data in context.
Read the piece →Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.
Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.
